Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 701-179-4 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Effect on fertility: via oral route
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 150 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Additional information
A study according to OECD 422 guideline and GLP was conducted (BASF SE, 2015) to provide data on the possible effects of the test item Octadecanoic acid, sulfo-, potassium salt on systemic and local toxicity and on reproductive performance of Wistar rats and the development of pups following daily oral administration of the test item via gavage. Concentrations of 0, 50, 150 and 500 mg/kg were given to male and female rats during a premating period of 2 weeks and during mating (1 week), up to a total of approximately 4 weeks for males and including gestation and lactation until postnatal day 4 (PN day 4) for females (up to a total of approximately 6 weeks). The substance was homogeneously distributed in the gavage liquids. The following test substance-related adverse effects/findings were noted:
Test group 3: 500 mg/kg bw/d octadecanoic acid, sulfo-, potassium salt
F0 PARENTAL ANIMALS CLINICAL EXAMINATIONS
• decreased food consumption during premating (up to -9%), gestation (up to -20%), and lactation (not statistically significant -10%) in females
• decreased body weight during lactation (up to -10%)
• piloerection shown by 3 females during lactation
REPRODUCTIVE PERFORMANCE
• no test substance-related adverse findings
CLINICAL PATHOLOGY
• no test substance-related adverse findings
PATHOLOGY
• no test substance-related adverse findings
F1 PUPS CLINICAL EXAMINATIONS/ GROSS FINDINGS
• decreased live birth index (64.2%)
• increase number of stillborn pups (35.8%) leading to 88.9% dams with stillborn pups
• increased perinatal loss (36.7%)
• decreased viability index (73%)
• increased number of pups found dead (4 pups)
• increased number of pups missing (cannibalized, 13 pups)
• decreased pup weights of both sexes at postnatal day 1 (-23.0%)
• decreased pup weight change between postnatal day 1 and 4 in pups of both sexes (-28.5%) were bases on a decreased pup weight change in male pups of -25.4%, and in female pups of -24.1% (not statistically significant)
• increased number of runts (10 males and 12 females)
• increased number of pups with post mortem autolyzes
• increased number of pups with discolored liver
• increased number of pups with empty stomach For the other dose groups (50 and 150 mg/kg) no effects were observed.
Under the conditions of this Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test, the oral administration by gavage of octadecanoic acid, sulfo-, potassium salt to Wistar rats revealed no signs of general systemic toxicity in male parental animals up to 500 mg/kg bw/d. Signs of systemic toxicity were observed in female parental animals at 500 mg/kg bw/d. Thus, the no observed adverse effect level (NOAEL) for general systemic toxicity was 500 mg/kg bw/d in male parental animals and 150 mg/kg bw/d in female parental animals. The no observed adverse effect level (NOAEL) for reproductive performance and fertility was 500 mg/kg bw/d in male and female Wistar rats. The NOAEL for developmental toxicity in the F1 progeny was 150 mg/kg bw/d.
Short description of key information:
OECD 422 (rat, oral, GLP, BASF SE, 2015): NOAEL = 150mg/kg bw/day
Effects on developmental toxicity
Description of key information
OECD 422 (rat, oral, GLP, BASF SE, 2015): NOAEL = 150mg/kg bw/day
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 150 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Additional information
A study according to OECD 422 guideline and GLP was conducted (BASF SE, 2015) to provide data on the possible effects of the test item Octadecanoic acid, sulfo-, potassium salt on systemic and local toxicity and on reproductive performance ofWistarrats and the development of pups following daily oral administration of the test item via gavage. Concentrations of 0, 50, 150 and 500 mg/kg were given to male and female rats during a premating period of 2 weeks and during mating (1 week), up to a total of approximately 4 weeks for males and including gestation and lactation until postnatal day 4 (PN day 4) for females (up to a total of approximately 6 weeks). The substance was homogeneously distributed in the gavage liquids.The following test substance-related adverse effects/findings were noted:
Test group 3: 500 mg/kg bw/d octadecanoic acid, sulfo-, potassium salt
F0 PARENTAL ANIMALS CLINICAL EXAMINATIONS
• decreased food consumption during premating (up to -9%), gestation (up to -20%), and lactation (not statistically significant -10%) in females
• decreased body weight during lactation (up to -10%)
• piloerection shown by 3 females during lactation
REPRODUCTIVE PERFORMANCE
• no test substance-related adverse findings
CLINICAL PATHOLOGY
• no test substance-related adverse findings
PATHOLOGY
• no test substance-related adverse findings
F1 PUPS CLINICAL EXAMINATIONS/ GROSS FINDINGS
• decreased live birth index (64.2%)
• increase number of stillborn pups (35.8%) leading to 88.9% dams with stillborn pups
• increased perinatal loss (36.7%)
• decreased viability index (73%)
• increased number of pups found dead (4 pups)
• increased number of pups missing (cannibalized, 13 pups)
• decreased pup weights of both sexes at postnatal day 1 (-23.0%)
• decreased pup weight change between postnatal day 1 and 4 in pups of both sexes (-28.5%) were bases on a decreased pup weight change in male pups of -25.4%, and in female pups of -24.1% (not statistically significant)
• increased number of runts (10 males and 12 females)
• increased number of pups with post mortem autolyzes
• increased number of pups with discolored liver
• increased number of pups with empty stomach For the other dose groups (50 and 150 mg/kg) no effects were observed.
Under the conditions of this Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test, the oral administration by gavage of octadecanoic acid, sulfo-, potassium salt to Wistar rats revealed no signs of general systemic toxicity in male parental animals up to 500 mg/kg bw/d. Signs of systemic toxicity were observed in female parental animals at 500 mg/kg bw/d. Thus, the no observed adverse effect level (NOAEL) for general systemic toxicity was 500 mg/kg bw/d in male parental animals and 150 mg/kg bw/d in female parental animals. The no observed adverse effect level (NOAEL) for reproductive performance and fertility was 500 mg/kg bw/d in male and female Wistar rats. The NOAEL for developmental toxicity in the F1 progeny was 150 mg/kg bw/d.
Justification for classification or non-classification
Based on the available data, the test substance shall be classified regarding developmental toxicity (cat 1B).
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.